Adhezion Biomedical
Founded Year
2001Stage
Acquired | AcquiredTotal Raised
$16.06MAbout Adhezion Biomedical
Adhezion Biomedical is a medical device company focused on the development and commercialization of cyanoacrylate-based surgical, wound management and infection prevention technologies for use in professional and consumer healthcare settings. The company was founded in 2001 and is based in Wyomissing, Pennsylvania. In June 2023, Adhezion Biomedical was acquired by H.B. Fuller Company. The term of the transaction were not disclosed.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Adhezion Biomedical Patents
Adhezion Biomedical has filed 58 patents.
The 3 most popular patent topics include:
- Acoustics
- Adhesives
- Aerodynamics
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/16/2020 | 12/7/2021 | Truffles (fungi), Tuber (fungus), Technical drawing, House types, Eggshell fossils | Grant |
Application Date | 3/16/2020 |
|---|---|
Grant Date | 12/7/2021 |
Title | |
Related Topics | Truffles (fungi), Tuber (fungus), Technical drawing, House types, Eggshell fossils |
Status | Grant |
Latest Adhezion Biomedical News
Jul 12, 2023
Adhesives firm Fuller Company acquires Adhezion Biomedical 12 July 2023 × The acquisition of Adhezion ─ which manufactures and distributes highly differentiated, proprietary cyanoacrylate technologies for surgical care, wound management, and infection prevention in healthcare settings ─ builds a platform of scale for H.B. Fuller in the topical skin bonding market, adding to capabilities attained from the company’s purchase of Tissue Seal in 2021 and providing vertically integrated adhesive manufacturing and packaging capability. The acquisition decisively positions H.B. Fuller for expansion in the medical adhesives industry and creates a solid, unique platform from which to scale and innovate in the healthcare adhesives space. Jim East, executive vice president, Hygiene, Health, and Consumable Adhesives, said: “This is a strategic move in support of our long-term growth strategy. H.B. Fuller products have been used around the world in medical applications for more than two decades, enabling new ideas and accelerating innovation. With our acquisition of Adhezion Biomedical, we will not only open new markets and diversify our portfolio, we will significantly strengthen our capabilities in the medical adhesives space, representing a milestone in our commitment to deliver greater value to our customers around the world.” With a team of approximately 50 employees, Adhezion Biomedical will operate within H.B. Fuller’s existing Hygiene, Health, and Consumable Adhesives global business unit to accelerate growth with new medical grade technology, in-depth application expertise, and reinforced ability to certify new innovations in the healthcare industry around the world.
Adhezion Biomedical Frequently Asked Questions (FAQ)
When was Adhezion Biomedical founded?
Adhezion Biomedical was founded in 2001.
Where is Adhezion Biomedical's headquarters?
Adhezion Biomedical's headquarters is located at One Meridian Blvd, Wyomissing.
What is Adhezion Biomedical's latest funding round?
Adhezion Biomedical's latest funding round is Acquired.
How much did Adhezion Biomedical raise?
Adhezion Biomedical raised a total of $16.06M.
Who are the investors of Adhezion Biomedical?
Investors of Adhezion Biomedical include H.B. Fuller Company, Paycheck Protection Program, Originate Ventures and Liberty Venture Partners.
Who are Adhezion Biomedical's competitors?
Competitors of Adhezion Biomedical include OcuNexus Therapeutics, Plurogen Therapeutics, Revance Therapeutics, Biofisica, Kytogenics Pharmaceuticals Limited and 10 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Adhezion Biomedical to Competitors
OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.
DermAvance Pharmaceuticals, a pharmaceutical company engaged in advanced technology applications for skin health and cosmetic dermatology, announced the acquisition of the North American rights for the Hyalogy Total Skin Care Line from Forlle'd in Japan.
PluroGen Therapeutics provides clinically advanced and advantaged burn, wound and skin care products. The company works closely with doctors, nurses, patients and healthcare institutions to provide the best products for burn, wound and skin care to help people have a better quality of life. The Company's primary platform is its core PluroGel surfactant technology which provides products with paradigm-shifting, superior and differentiated Core, Bio-Physical, and Performance Functions resulting in unique and advantaged Multi-Function products.
Aero Pharmaceuticals, Inc markets lines of dermatological products under Baker Cummins Dermatologicals. Baker Cummins Dermatologicals markets a line of scalp and skin care products that can be used to treat dry skin and scalp conditions commonly seen.
KeraCure is developing wound healing therapies through development of a platform technology that will simplify usage of cell-based therapies.
ISW Group is a pharmaceutical company that researches and aims to develop FDA approved topical products for the management and treatment of acute and chronic inflammatory skin conditions. ISW Group's research program focuses on acute and chronic dermatologic irritation and inflammation associated with dermatitis, Pseudofolliculitis barbae, burn care and wound healing.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
